Low Incidence of Inflammatory Bowel Disease Adverse Events in Adalimumab Clinical Trials Across Nine Different Diseases

OBJECTIVE: Adalimumab is approved for treatment of Crohn’s disease and ulcerative colitis. Thus, we postulated that exacerbation or new‐onset of inflammatory bowel disease (IBD) would be rare events in patients treated with adalimumab for non‐IBD indications. The objective was to evaluate the incide...

Descripción completa

Detalles Bibliográficos
Autores principales: Elewaut, Dirk, Braun, Jürgen, Anderson, Jaclyn K., Arikan, Dilek, Chen, Su, Hojnik, Maja, De Craemer, Ann-Sophie, Curtis, Jeffrey R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Spondyloarthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898340/
https://www.ncbi.nlm.nih.gov/pubmed/32100944
http://dx.doi.org/10.1002/acr.24175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898340/
https://www.ncbi.nlm.nih.gov/pubmed/32100944
http://dx.doi.org/10.1002/acr.24175

Ejemplares similares